4724.TWO Meribank Biotech Co., Ltd
- Market cap
- TWD 852M
- P/E
- -
- P/B
- 0.74x
- ROE
- -6.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4724.TWO undervalued?
Graham numberThe Graham number of Meribank Biotech Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Meribank Biotech Co., Ltd fundamental analysis
No fundamental analysis for Meribank Biotech Co., Ltd yet.
Meribank Biotech Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.
Full company profileMeribank Biotech Co., Ltd financial statements
Meribank Biotech Co., Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 161M | 194M | 163M | 180M | 234M | 366M | 472M |
| Gross Profit | 93.0M | 115M | 90.1M | 94.8M | 139M | 194M | 202M |
| Operating Income | -57.4M | -70.1M | -97.2M | -110M | -123M | -86.7M | -47.3M |
| EBITDA | -47.2M | -29.9M | -68.6M | -64.7M | -92.6M | -6.83M | 89.6M |
| Net Income | -59.9M | -54.5M | -99.2M | -102M | -125M | -94.7M | -81.5M |
| EPS | -1.13 | -1.02 | -1.63 | -1.62 | -1.99 | -1.19 | -0.85 |
| Balance Sheet | |||||||
| Total Assets | 693M | 730M | 947M | 846M | 1.06B | 2.68B | 2.88B |
| Total Liabilities | 259M | 347M | 361M | 373M | 391M | 1.46B | 1.62B |
| Shareholders' Equity | 434M | 383M | 586M | 471M | 662M | 1.21B | 1.25B |
| Cash & Short-term Investments | 105M | 97.3M | 286M | 208M | 399M | 165M | 97.4M |
| Total Debt | 18.7M | 69.9M | 53.0M | 45.8M | 34.0M | 943M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -3.74M | -17.7M | -23.0M | -41.3M | -29.7M | -38.1M | 89.5M |
| Capital Expenditure | 5.28M | 7.53M | 7.52M | 4.25M | 6.68M | 344M | 4.89M |
| Free Cash Flow | -9.02M | -25.3M | -30.5M | -45.6M | -36.4M | -382M | 84.6M |
| Ratios | |||||||
| ROE | -13.8% | -14.2% | -16.9% | -21.7% | -18.9% | -7.9% | -6.5% |
| ROA | -8.6% | -7.5% | -10.5% | -12.1% | -11.8% | -3.5% | -2.8% |
| Net Profit Margin | -37.2% | -28.0% | -60.8% | -56.7% | -53.5% | -25.8% | -17.3% |
| Debt to Equity | 0.04x | 0.18x | 0.09x | 0.10x | 0.05x | 0.78x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Meribank Biotech Co., Ltd dividends
Meribank Biotech Co., Ltd has not paid dividends in the last 7 fiscal years.
Who owns Meribank Biotech Co., Ltd
Ownership data of Meribank Biotech Co., Ltd is not available yet.
Meribank Biotech Co., Ltd company profile
- Company name
- Meribank Biotech Co., Ltd
- Ticker
- 4724.TWO
- ISIN
- TW0004724000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.68, Neihu Road, Taipei, Taiwan, 11493
- Phone
- 886 2 8978 7777
- Website
- meribank.com.tw
About Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.
Meribank Biotech Co., Ltd management
2- Mr. Jian-Fang CaiManager & Vice Chairman
- Yuxia ChenAccounting Supervisor